December 8th 2010: The 6th annual Dutch Life Sciences and Health conference was held in de Beurs van Berlage, Amsterdam. Willem de Laat, Managing Director at Life Sciences Health, talks about 'Innovation to commercialization'.
Perficient is a leading digital transformation consulting firm that provides services to Global 2000 companies including information technology, management consulting, and creative capabilities. It delivers vision, execution, and value through outstanding digital experiences, business optimization, and industry solutions. The document discusses several trends in healthcare and clinical trials, including employing mobile applications in research, investing in social listening tools, and keeping clinical trial data secure.
The document provides an overview of life science trends in 2016, focusing on regenerative medicine. It includes interviews with thought leaders in regenerative medicine on the past, present and future of the field. The document also covers research and innovation in areas like cancer immunotherapy and personalized medicine. It discusses fundamental trends in the industry including biosimilars, biopharma blockbusters, gene editing treatments and digital medicine. The document summarizes investment and deal making activity as well as regulatory issues and developments in healthcare related to areas like antibiotics and whole genome sequencing.
By 2018, digital drug launches and social media marketing will be standard for most major pharmaceutical companies as digital technologies transform the industry. By 2019, half of the top 100 life science companies will have conducted at least one clinical trial using wearable devices, and big data projects will have moved from pilots to production at 30% of life science research organizations. Global health data is growing rapidly and becoming more open, requiring companies to make use of this additional information to gain advantages over competitors.
U.S. Life Sciences industry trends and clustersJLL
Despite higher rents and labor costs, Life Sciences firms continue to flock to premier markets.
The need for specialized talent—often at the PhD level—has historically driven Life Sciences organizations to markets with reputable colleges and universities, like Boston, Raleigh-Durham and San Francisco.
Flip through for more on top Life Sciences markets in the United States and abroad, and trends impacting the industry.
For additional information, visit: us.jll.com/life-sciences-trends.
Digital Innovation Impact in Life Sciences JulyPaul Gulbin
Five digital trends are radically impacting the life sciences industry: 1) Internet of My Things using devices to provide personalized healthcare, 2) Connected Economy where hardware and sensors produce better health outcomes, 3) Agile Platform combining different systems and data sources to redefine healthcare, 4) Enterprise Insight using big data and analytics for smarter medical systems, and 5) Digital Healthcare improving care through telehealth and remote monitoring. These trends are being driven by innovations like wearable devices, connected medical products, 3D printing, predictive maintenance through IoT, and integrated healthcare platforms.
The document outlines various predictions for the healthcare industry in 2016-2019. Key predictions include: 1) By 2019, 25% of healthcare organizations will use digital wayfinding tools and 25% will have chief data officers; 2) By 2018, risk-based contracting will increase to 30% of provider payments and virtual assistants will be used for 25% of medical decisions; 3) Technologies like wearables, computer-assisted surgery, and cognitive computing will be increasingly adopted between 2016-2018 to improve care and reduce costs.
This document provides information about a digital transformation conference for the pharmaceutical industry to be held in Copenhagen on April 13-14, 2016. The conference aims to share digital initiatives for patients and healthcare professionals and discuss how organizations can better utilize online opportunities. It will feature keynote speakers from companies like LEO Innovation Lab and Google discussing how digital technologies are changing pharma business models and engagement. The agenda also includes sessions on using social media, real-world evidence, direct-to-consumer communication, and enhancing customer experiences through data-driven insights. The conference seeks to inspire participants to embrace new digital channels and approaches to collaborating with customers.
Pharma’s future has never looked more promising – or more ominous.
Major scientific, technological and socioeconomic changes will revive
the industry’s fortunes in another decade, but capitalising on these
trends will entail making crucial decisions first
Perficient is a leading digital transformation consulting firm that provides services to Global 2000 companies including information technology, management consulting, and creative capabilities. It delivers vision, execution, and value through outstanding digital experiences, business optimization, and industry solutions. The document discusses several trends in healthcare and clinical trials, including employing mobile applications in research, investing in social listening tools, and keeping clinical trial data secure.
The document provides an overview of life science trends in 2016, focusing on regenerative medicine. It includes interviews with thought leaders in regenerative medicine on the past, present and future of the field. The document also covers research and innovation in areas like cancer immunotherapy and personalized medicine. It discusses fundamental trends in the industry including biosimilars, biopharma blockbusters, gene editing treatments and digital medicine. The document summarizes investment and deal making activity as well as regulatory issues and developments in healthcare related to areas like antibiotics and whole genome sequencing.
By 2018, digital drug launches and social media marketing will be standard for most major pharmaceutical companies as digital technologies transform the industry. By 2019, half of the top 100 life science companies will have conducted at least one clinical trial using wearable devices, and big data projects will have moved from pilots to production at 30% of life science research organizations. Global health data is growing rapidly and becoming more open, requiring companies to make use of this additional information to gain advantages over competitors.
U.S. Life Sciences industry trends and clustersJLL
Despite higher rents and labor costs, Life Sciences firms continue to flock to premier markets.
The need for specialized talent—often at the PhD level—has historically driven Life Sciences organizations to markets with reputable colleges and universities, like Boston, Raleigh-Durham and San Francisco.
Flip through for more on top Life Sciences markets in the United States and abroad, and trends impacting the industry.
For additional information, visit: us.jll.com/life-sciences-trends.
Digital Innovation Impact in Life Sciences JulyPaul Gulbin
Five digital trends are radically impacting the life sciences industry: 1) Internet of My Things using devices to provide personalized healthcare, 2) Connected Economy where hardware and sensors produce better health outcomes, 3) Agile Platform combining different systems and data sources to redefine healthcare, 4) Enterprise Insight using big data and analytics for smarter medical systems, and 5) Digital Healthcare improving care through telehealth and remote monitoring. These trends are being driven by innovations like wearable devices, connected medical products, 3D printing, predictive maintenance through IoT, and integrated healthcare platforms.
The document outlines various predictions for the healthcare industry in 2016-2019. Key predictions include: 1) By 2019, 25% of healthcare organizations will use digital wayfinding tools and 25% will have chief data officers; 2) By 2018, risk-based contracting will increase to 30% of provider payments and virtual assistants will be used for 25% of medical decisions; 3) Technologies like wearables, computer-assisted surgery, and cognitive computing will be increasingly adopted between 2016-2018 to improve care and reduce costs.
This document provides information about a digital transformation conference for the pharmaceutical industry to be held in Copenhagen on April 13-14, 2016. The conference aims to share digital initiatives for patients and healthcare professionals and discuss how organizations can better utilize online opportunities. It will feature keynote speakers from companies like LEO Innovation Lab and Google discussing how digital technologies are changing pharma business models and engagement. The agenda also includes sessions on using social media, real-world evidence, direct-to-consumer communication, and enhancing customer experiences through data-driven insights. The conference seeks to inspire participants to embrace new digital channels and approaches to collaborating with customers.
Pharma’s future has never looked more promising – or more ominous.
Major scientific, technological and socioeconomic changes will revive
the industry’s fortunes in another decade, but capitalising on these
trends will entail making crucial decisions first
Artificial Intelligence in Pharmaceutical ScienceAhmed Obaidullah
AI And Machine Learning Are Changing Our World And Powering The 4th Industrial Revolution. Learn About The 5 Ways AI Is Changing Our World For The Better At Salzburg Global Today! Inspire Action. Expand Collaboration. Transform Systems. Bridge Divides.
Key lessons learned from the worldwide pandemic
Keynote presentation at the Digital Transformation of Pharmaceutical Industry conference organised by United Journal and Conferences on April 13th 2021
This document discusses concepts related to the global health-tech industry. It provides an overview of key topics including the healthcare and life sciences industry in 2020, technologies and startups disrupting the status quo, a focus on the medical device industry globally and in India, and a concept note on syringe counterfeiting. The document also analyzes funding trends in 2020, highlights major disruptors like telemedicine, and provides snapshots on medical devices and new anti-counterfeiting technologies.
This document provides predictions for changes coming to the US healthcare system in 2017 and beyond. It predicts that the Affordable Care Act will undergo significant changes. It also expects the sale of health insurance across state lines, creating a new payment dynamic for providers. The document predicts that government funding to hospitals will be reduced, forcing cost cutting that will threaten higher compensation for providers. It concludes that providers should take control of their future by becoming entrepreneurs rather than relying on medical corporations. Clinic Service can help providers navigate these changes and ensure proper billing and payment.
This presentation summarizes our research on 40 companies from around the world that are leveraging Artificial Intelligence to improve the Healthcare Industry. They are all well-funded, have highly qualified CEOs & Boards, and are poised to achieve their product development milestones.
The I-Square Ventures proprietary rating algorithm indicates that almost all of these companies will receive more funding, and/or be acquired by larger companies.
Alex Ermolaev at AI Frontiers : Major Applications of AI in HealthcareAI Frontiers
The latest AI advances have the potential to massively improve our health and well being. However, most of the work is yet to be done. In this talk, we will explore the most important opportunities for AI in healthcare. For example, we will explore how AI can diagnose major life-threatening conditions even before those conditions emerge. We will talk about AI ability to recommend dramatically more effective and less harmful treatment plans based on AI understanding of patient's medical history and current conditions. Finally, we will talk about AI role in making our healthcare system effective and affordable for everyone.
This document summarizes the findings of a study on the global mHealth app market conducted by research2guidance, a market research company focused on the mobile app ecosystem. Some key findings of the study include:
- The majority of mHealth app publishers have less than 10 apps and are not achieving their goals or seeing significant financial returns.
- Features like reminders that are easy to implement are seen as the most effective for changing patient behavior.
- Patients and healthcare providers are expected to benefit the most from mHealth over the next 5 years, while providers face the biggest threats to their core business models.
mHealth Israel_Future of Integrated Individualized Healthcare_Roche DiagnosticsLevi Shapiro
Presentation by Alexandra Eberhard, Sr. Director, Global Business Development, Roche Diagnostics on the "Future of Integrated Individualized Healthcare". Includes background about Roche Diagnostics and investments in innovation. Overview of Roche products and solutions with a portfolio covering the entire spectrum of diagnostics users. Emphasis on the triple aim of healthcare- The power of data and technology to enable the transformation from volume- to value-based healthcare. Interest in data for Pharma - drive more efficient R&D; DIA - develop novel patient care Dx solutions. Focus on the needs of labs, physicians & payers for better patient health. A suite of digital solutions that improve clinical & business outcomes. Suite of solutions to optimize the lab. Translating data into insights to achieve financial goals. A move from volume- to value-based care. New opportunities in the disease continuum- Holistic solutions approach. Expanding the focus towards earlier in the patient journey. Doing now what patients need next. Contact Alexandra Vallon-Eberhard, PhD MBA; Sr. Director Global Business Development; Diagnostics Lead for Innovation in Israel; Based in Basel, Switzerland; Email: alexandra.vallon_eberhard@roche.com
New AI innovations bring the healthcare sector to a CAGR of 54.5% by 2025 Bella Harris
The healthcare sector explores AI with innovations focusing on improved treatments. With this, AI in the healthcare industry is anticipated to grow with a healthy CAGR of more than 54.5% by 2025.
3 Digital Healthcare Trends That We Can Expect to See More of in 2017Jeremy Barbera
Clinical trials will increasingly utilize medical devices and digital monitoring of patients to gather health data in real time, allowing researchers to reach conclusions more quickly compared to periodic patient visits. Wearable devices that monitor health metrics like vital signs will become more common, sending steady streams of data to healthcare providers for remote patient monitoring. Consumers are also adopting more digital health tools to self-monitor conditions, with over half of consumers now using at least three digital health technologies, up significantly from the previous year.
2019-2020: Blip or shift? Key trends in the HCP mixAcross Health
This document discusses key trends in the healthcare professional mix from 2019-2020. It provides an agenda for a webinar covering emerging changes at the customer and pharmaceutical company levels, and how to reimagine the future. Survey results show over 60% of specialists saw some improvement in biopharma digital content during the pandemic, but only 21% saw a strong boost. The importance and satisfaction of pharmaceutical digital offerings increased, but there is still a large gap and only a few companies providing relevant content. The webinar aims to help pharmaceutical companies translate strategic priorities into high-impact customer engagement strategies using omnichannel approaches.
CPL Business Consultants provides market and technology consulting services and strategic business advice to clients in the food, agriculture, and biotechnology industries. They have a team of experienced consultants with scientific backgrounds and expertise in relevant fields. Their services include strategic analysis, market assessments, technology evaluations, and action plans to help clients identify opportunities and develop effective business strategies. They have over 120 clients globally, most of which are medium to large companies in the food/health ingredients, biotechnology, and agriculture sectors.
Medtronic Inc. is one of the largest medical device manufacturers in North America, founded in 1949 and headquartered in Minneapolis. It has two major business units: Cardiovascular and Restorative Therapies. The document analyzes Medtronic using Porter's Five Forces, a SWOT analysis, and discusses risks, technology applications, a McKinsey analysis, financial analysis, and social responsibilities. It makes recommendations, including settling lawsuits, maintaining brand reputation, pursuing emerging markets, and continuing investment in technology development.
This document discusses the use of artificial intelligence in the pharmaceutical industry. It covers how AI can be applied across various areas like drug discovery, clinical trials, manufacturing, and healthcare. Some key benefits mentioned are reducing drug development time and costs, improving success rates of clinical trials, and optimizing manufacturing processes. Challenges to adoption like data and skills gaps are also summarized.
The State Of Mobility In Healthcare - WebinarInnopplinc
Webinar that focused on the state of mobility in the Healthcare industry. This webinar dicussed:
- Why are mobile healthcare apps on the rise?
- Is developing a healthcare mobile app right for your business?
- Gave a demo of some of the healthcare apps developed by Innoppl
PDF of our webinar from Thursday, July 30th, 2015.
Wardell, Future of Digital Health, Leerink Research 2014-10Steven Wardell
The document discusses the emerging digital health sector and identifies six investment themes driving opportunities:
1) Consumer Empowerment, 2) Automation, 3) Connected Health, 4) Population Health, 5) Big Data, and 6) Healthcare IT. It notes that while investment in digital health companies has grown, their stock performance has lagged the broader market. The document initiates coverage on six digital health stocks and sees opportunities for companies in online health media, consumer tools, and healthcare automation.
Everything you want to know about role of artificial intelligence in drug discovery.
Artificial intelligence in health care and pharmacy, drug discovery, tensorflow, python,
deep neural network, GANs
AI in drug discovery and development
AI in clinical trials
The document discusses Illumina's role in advancing precision medicine through next-generation sequencing and data analytics. It notes that while sequencing costs have decreased dramatically, challenges remain in interpreting, integrating, and analyzing the large volumes of genomic and other healthcare data. Illumina aims to develop comprehensive, patient-centric analytics platforms and knowledgebases to help address these challenges and enable more effective prevention, diagnosis, and treatment based on a patient's genetics, environment, and lifestyle. The success of these efforts will be measured by improvements in patient outcomes, healthcare costs and efficiencies, and changes in clinical practice guided by integrated genomic and clinical data analysis.
Open 2013: Innovation Commercialization and Licensingthe nciia
This document summarizes a presentation on incorporating university innovation commercialization projects into graduate business courses. It discusses researching the utility of having students develop commercialization plans for university-owned intellectual property. The results showed students created multiple commercialization plans per class. Their work created value, reduced the administrative workload, and improved the expected time to market for some innovations compared to traditional technology transfer office processes. While more research is needed, this demonstrates the potential dual benefit of educating students with practical projects while also aiding the commercialization of university intellectual property.
1) InnovationSpeeder aims to make the innovation commercialization process focused, fast, and efficient by maximizing customer value and fostering business formation.
2) It takes a holistic approach to innovation, developing customership, business models, user experience, and products/services simultaneously using proven methods.
3) InnovationSpeeder supports commercialization in all phases for startups, corporations, research institutes, and innovators through services tailored to each innovation process such as concept development, market assessment, value design, and commercialization campaigns.
Artificial Intelligence in Pharmaceutical ScienceAhmed Obaidullah
AI And Machine Learning Are Changing Our World And Powering The 4th Industrial Revolution. Learn About The 5 Ways AI Is Changing Our World For The Better At Salzburg Global Today! Inspire Action. Expand Collaboration. Transform Systems. Bridge Divides.
Key lessons learned from the worldwide pandemic
Keynote presentation at the Digital Transformation of Pharmaceutical Industry conference organised by United Journal and Conferences on April 13th 2021
This document discusses concepts related to the global health-tech industry. It provides an overview of key topics including the healthcare and life sciences industry in 2020, technologies and startups disrupting the status quo, a focus on the medical device industry globally and in India, and a concept note on syringe counterfeiting. The document also analyzes funding trends in 2020, highlights major disruptors like telemedicine, and provides snapshots on medical devices and new anti-counterfeiting technologies.
This document provides predictions for changes coming to the US healthcare system in 2017 and beyond. It predicts that the Affordable Care Act will undergo significant changes. It also expects the sale of health insurance across state lines, creating a new payment dynamic for providers. The document predicts that government funding to hospitals will be reduced, forcing cost cutting that will threaten higher compensation for providers. It concludes that providers should take control of their future by becoming entrepreneurs rather than relying on medical corporations. Clinic Service can help providers navigate these changes and ensure proper billing and payment.
This presentation summarizes our research on 40 companies from around the world that are leveraging Artificial Intelligence to improve the Healthcare Industry. They are all well-funded, have highly qualified CEOs & Boards, and are poised to achieve their product development milestones.
The I-Square Ventures proprietary rating algorithm indicates that almost all of these companies will receive more funding, and/or be acquired by larger companies.
Alex Ermolaev at AI Frontiers : Major Applications of AI in HealthcareAI Frontiers
The latest AI advances have the potential to massively improve our health and well being. However, most of the work is yet to be done. In this talk, we will explore the most important opportunities for AI in healthcare. For example, we will explore how AI can diagnose major life-threatening conditions even before those conditions emerge. We will talk about AI ability to recommend dramatically more effective and less harmful treatment plans based on AI understanding of patient's medical history and current conditions. Finally, we will talk about AI role in making our healthcare system effective and affordable for everyone.
This document summarizes the findings of a study on the global mHealth app market conducted by research2guidance, a market research company focused on the mobile app ecosystem. Some key findings of the study include:
- The majority of mHealth app publishers have less than 10 apps and are not achieving their goals or seeing significant financial returns.
- Features like reminders that are easy to implement are seen as the most effective for changing patient behavior.
- Patients and healthcare providers are expected to benefit the most from mHealth over the next 5 years, while providers face the biggest threats to their core business models.
mHealth Israel_Future of Integrated Individualized Healthcare_Roche DiagnosticsLevi Shapiro
Presentation by Alexandra Eberhard, Sr. Director, Global Business Development, Roche Diagnostics on the "Future of Integrated Individualized Healthcare". Includes background about Roche Diagnostics and investments in innovation. Overview of Roche products and solutions with a portfolio covering the entire spectrum of diagnostics users. Emphasis on the triple aim of healthcare- The power of data and technology to enable the transformation from volume- to value-based healthcare. Interest in data for Pharma - drive more efficient R&D; DIA - develop novel patient care Dx solutions. Focus on the needs of labs, physicians & payers for better patient health. A suite of digital solutions that improve clinical & business outcomes. Suite of solutions to optimize the lab. Translating data into insights to achieve financial goals. A move from volume- to value-based care. New opportunities in the disease continuum- Holistic solutions approach. Expanding the focus towards earlier in the patient journey. Doing now what patients need next. Contact Alexandra Vallon-Eberhard, PhD MBA; Sr. Director Global Business Development; Diagnostics Lead for Innovation in Israel; Based in Basel, Switzerland; Email: alexandra.vallon_eberhard@roche.com
New AI innovations bring the healthcare sector to a CAGR of 54.5% by 2025 Bella Harris
The healthcare sector explores AI with innovations focusing on improved treatments. With this, AI in the healthcare industry is anticipated to grow with a healthy CAGR of more than 54.5% by 2025.
3 Digital Healthcare Trends That We Can Expect to See More of in 2017Jeremy Barbera
Clinical trials will increasingly utilize medical devices and digital monitoring of patients to gather health data in real time, allowing researchers to reach conclusions more quickly compared to periodic patient visits. Wearable devices that monitor health metrics like vital signs will become more common, sending steady streams of data to healthcare providers for remote patient monitoring. Consumers are also adopting more digital health tools to self-monitor conditions, with over half of consumers now using at least three digital health technologies, up significantly from the previous year.
2019-2020: Blip or shift? Key trends in the HCP mixAcross Health
This document discusses key trends in the healthcare professional mix from 2019-2020. It provides an agenda for a webinar covering emerging changes at the customer and pharmaceutical company levels, and how to reimagine the future. Survey results show over 60% of specialists saw some improvement in biopharma digital content during the pandemic, but only 21% saw a strong boost. The importance and satisfaction of pharmaceutical digital offerings increased, but there is still a large gap and only a few companies providing relevant content. The webinar aims to help pharmaceutical companies translate strategic priorities into high-impact customer engagement strategies using omnichannel approaches.
CPL Business Consultants provides market and technology consulting services and strategic business advice to clients in the food, agriculture, and biotechnology industries. They have a team of experienced consultants with scientific backgrounds and expertise in relevant fields. Their services include strategic analysis, market assessments, technology evaluations, and action plans to help clients identify opportunities and develop effective business strategies. They have over 120 clients globally, most of which are medium to large companies in the food/health ingredients, biotechnology, and agriculture sectors.
Medtronic Inc. is one of the largest medical device manufacturers in North America, founded in 1949 and headquartered in Minneapolis. It has two major business units: Cardiovascular and Restorative Therapies. The document analyzes Medtronic using Porter's Five Forces, a SWOT analysis, and discusses risks, technology applications, a McKinsey analysis, financial analysis, and social responsibilities. It makes recommendations, including settling lawsuits, maintaining brand reputation, pursuing emerging markets, and continuing investment in technology development.
This document discusses the use of artificial intelligence in the pharmaceutical industry. It covers how AI can be applied across various areas like drug discovery, clinical trials, manufacturing, and healthcare. Some key benefits mentioned are reducing drug development time and costs, improving success rates of clinical trials, and optimizing manufacturing processes. Challenges to adoption like data and skills gaps are also summarized.
The State Of Mobility In Healthcare - WebinarInnopplinc
Webinar that focused on the state of mobility in the Healthcare industry. This webinar dicussed:
- Why are mobile healthcare apps on the rise?
- Is developing a healthcare mobile app right for your business?
- Gave a demo of some of the healthcare apps developed by Innoppl
PDF of our webinar from Thursday, July 30th, 2015.
Wardell, Future of Digital Health, Leerink Research 2014-10Steven Wardell
The document discusses the emerging digital health sector and identifies six investment themes driving opportunities:
1) Consumer Empowerment, 2) Automation, 3) Connected Health, 4) Population Health, 5) Big Data, and 6) Healthcare IT. It notes that while investment in digital health companies has grown, their stock performance has lagged the broader market. The document initiates coverage on six digital health stocks and sees opportunities for companies in online health media, consumer tools, and healthcare automation.
Everything you want to know about role of artificial intelligence in drug discovery.
Artificial intelligence in health care and pharmacy, drug discovery, tensorflow, python,
deep neural network, GANs
AI in drug discovery and development
AI in clinical trials
The document discusses Illumina's role in advancing precision medicine through next-generation sequencing and data analytics. It notes that while sequencing costs have decreased dramatically, challenges remain in interpreting, integrating, and analyzing the large volumes of genomic and other healthcare data. Illumina aims to develop comprehensive, patient-centric analytics platforms and knowledgebases to help address these challenges and enable more effective prevention, diagnosis, and treatment based on a patient's genetics, environment, and lifestyle. The success of these efforts will be measured by improvements in patient outcomes, healthcare costs and efficiencies, and changes in clinical practice guided by integrated genomic and clinical data analysis.
Open 2013: Innovation Commercialization and Licensingthe nciia
This document summarizes a presentation on incorporating university innovation commercialization projects into graduate business courses. It discusses researching the utility of having students develop commercialization plans for university-owned intellectual property. The results showed students created multiple commercialization plans per class. Their work created value, reduced the administrative workload, and improved the expected time to market for some innovations compared to traditional technology transfer office processes. While more research is needed, this demonstrates the potential dual benefit of educating students with practical projects while also aiding the commercialization of university intellectual property.
1) InnovationSpeeder aims to make the innovation commercialization process focused, fast, and efficient by maximizing customer value and fostering business formation.
2) It takes a holistic approach to innovation, developing customership, business models, user experience, and products/services simultaneously using proven methods.
3) InnovationSpeeder supports commercialization in all phases for startups, corporations, research institutes, and innovators through services tailored to each innovation process such as concept development, market assessment, value design, and commercialization campaigns.
University of Southern Indiana
Technology Commercialization Academy
USI’s Technology Commercialization Academy (TCA) challenges students to go from brainstorming ideas around U.S. Navy technology to launching new commercial ventures in 11 weeks over the summer. The goal is direct regional economic impact of USI students. The TCA recruits students from all fields of study and forms multidisciplinary teams of four. Via this paid fellowship, USI students gain real experience in the commercialization process, multidisciplinary collaboration, resource development, and industry familiarization, allowing them to play a role in transforming a region. The TCA is not an academic exercise. Students learn to fail, persevere, and pivot to better opportunities. They are treated as professionals, with all the soft and hard skills that implies, including accountability to their peers and the program. The TCA cultivates high-tech commercialization in southwest Indiana, trains the business leaders of tomorrow, and seeds startup companies. This provides USI an opportunity to home grow our own talent, make that talent feel invested in our region, and, thereby, retain that talent and their potential impact on our economy.
Mark Bernhard, Associate Provost for Outreach and Engagement, University of Southern Indiana
Jason Salstrom, Manager, Technology Commercialization, University of Southern Indiana
This document provides an overview of the Biology and Life Science class for the 2012-2013 school year taught by Julie Pen. It outlines what will be studied including the scientific method, cells, genetics, evolution, and human body systems. It also discusses life on Earth, the hierarchy of life from atoms to the biosphere, and the key aspects of the scientific method including making observations and hypotheses, designing experiments, collecting data, and drawing conclusions.
The document discusses innovation and patenting trends in ASEAN countries based on two presentations given at a 2016 innovation forum. It finds that while research output has increased across ASEAN nations from 2006 to 2015, only Singapore consistently performs above world average. Patent filings from ASEAN countries have also grown significantly from 2012 to 2014, with resident filings increasing from 8.6% in 2005 to 12.4% in 2014. Singapore leads ASEAN in terms of patent volumes and quality, though other countries like Malaysia and Thailand are increasing their output. Qualcomm is among the most prolific patenters across several ASEAN nations.
This document discusses intellectual property (IP) in Malaysia, including the chain of IP activities, types of IP, IP as tangible and intangible property, reasons for IP protection, IP as a transferable property, the legal framework and international conventions governing IP, key Malaysian IP laws, and strategies for commercializing and enforcing IP rights. It outlines the creation, protection, and commercialization process for various forms of IP including copyrights, trademarks, patents, industrial designs, geographical indications, and confidential information.
State of technology and innovation (2017 edition)Patrick Savalle
Technology is progressing rapidly in many areas such as 3D printing, autonomous vehicles, the Internet of Things, and artificial intelligence. However, there are also major challenges and ethical issues that need to be addressed regarding privacy, security, and control over emerging technologies. Truly transformative technologies like room temperature superconductors, anti-gravity devices, or replicators are still far in the future if ever possible. Overall the document discusses both the promise and challenges of new and future technologies.
10 Best Locations for Lifesciences Jobs in the World | The Lifesciences MagazineThe Lifesciences Magazine
Demand for life science specialists with expertise in multiple worldwide markets is rising as the globalization of the sector continues and the need for novel medical solutions skyrockets.
BreatheSuite is a medical device startup that has developed a smartphone-based spirometer to diagnose respiratory diseases like asthma and COPD. It was founded by three graduate students and has advisors from UW Medicine and global health non-profits. BreatheSuite aims to improve diagnosis of respiratory diseases globally by making low-cost spirometry accessible on any phone. Clinical trials have found BreatheSuite results are identical to traditional spirometers. It sees market opportunities in pharmaceutical clinical trials, developing countries, and existing customers include global health non-profits.
Catalonia has a large biotechnology sector concentrated around Barcelona, with over 1,150 entities including 268 biotech companies employing over 29,000 people. Catalonia contributes 29.4% of Spain's total biotech turnover of €15.6 billion annually from local initiatives despite making up only 20.5% of Spanish biotech companies. Catalonia has strong academic and research institutions that support its biotech industry, including 12 universities (10 offering life sciences), 150 research centers (60 in life sciences), 21 CSIC centers, and 215 hospitals.
Nestlé is expanding into the healthcare field through its new division, Nestlé Health Science. The presentation discusses opportunities in healthcare given trends of aging populations and increasing chronic diseases. It introduces Nestlé Health Science's vision to provide personalized nutrition solutions for medical conditions. Currently, Nestlé has a healthcare nutrition business and is expanding its scientific platforms and diagnostic capabilities through acquisitions to build a transformational healthcare business over the next 5 years.
PwC is a global professional services firm that provides audit, tax, and consulting services. It has established a Personalized Medicine practice to help clients address key healthcare trends and advance personalized healthcare. PwC has worked on various personalized medicine initiatives including establishing research institutes and facilitating strategic partnerships between organizations. Information technology and diagnostics will be important foundations supporting the development of personalized medicine.
PwC is a global professional services firm that provides audit, tax, and consulting services. It has established a Personalized Medicine practice to help clients respond to trends in personalized healthcare. PwC has worked on several initiatives involving personalized medicine, including establishing a genome research institute in Arizona and facilitating partnerships between institutions in the US and Luxembourg to advance bioscience research. PwC utilizes surveys, interviews, and research to develop reports on trends in healthcare, including the growth of personalized medicine.
Life & health Sciences Horizon Panel ReportEuroBioForum
The document summarizes a report by the Life & Health Sciences Horizon Panel on opportunities in Northern Ireland's growing life and health sciences sector. Key points include:
- The sector is an important part of the Northern Ireland economy, with over 60 companies employing 4,000 people and £310 million in combined turnover.
- Significant public and private investment has supported research infrastructure and collaboration between industry and academia.
- Globally, demand is rising for effective medicines and healthcare as populations age and diseases change, creating opportunities for growth. The report makes strategic recommendations to maximize economic returns for Northern Ireland.
Neuroscience is poised for increased deal activity after a period of setbacks. Advances in clinical trial design, imaging, and biomarkers are driving interest in neuroscience drugs. Venture funding and licensing deals in neurology and psychiatry totaled billions from 2005-2014, though M&A activity was lower. Recent large neuroscience acquisitions by companies like Celgene, Teva, and Biogen have sparked renewed enthusiasm. Experts predict precision medicine approaches will increase dealmaking as neurological diseases are further subtyped genetically.
Growing Stronger Research Fund Overview Jan 2012 For DonorsAmer Haider
Growing Stronger Research Fund aims to accelerate medical research to improve quality of life for people with Achondroplasia, the most common form of dwarfism. Their goal is to eliminate the need for multiple orthopedic surgeries by developing drug therapies. They are currently funding four research strategies, including blocking expression of the mutant gene or disabling the mutant protein. Their next steps are to raise $600,000 over three years to support additional lab testing and advance promising strategies toward clinical trials and approval.
The document summarizes presentations from startups at a Healthtech Innovation Queensland event. It introduces QHeart Medical, which is developing a device called BioQ CA to treat heart failure by reducing aortic stiffness. GravityFit was presented as developing an exercise system based on 30 years of research into the sensory effect of gravity. The document also summarizes Audeara, which is creating an autonomous ear screening device to address the problem of high rates of ear disease, particularly in remote communities.
While many companies are contributing to the battle against the pandemic, Deep Tech startups are trying to overcome scientific challenges to help with prevention, testing or treatment in novel and scalable ways.
This live event organized by SOSV brings together investors who have backed dozens of relevant startups, to get a sense of:
- The variety of solutions being developed,
- Their potential outcomes,
- The broader role and opportunities of deep tech investment.
SPEAKERS
- Seth Bannon, Founding Partner, Fifty Years
- Jun Axup, PhD, Chief Science Officer & Partner, IndieBio / SOSV
- Alex Morgan, MD PhD, Partner, Khosla Ventures
MODERATORS
- Julie Wolf, PhD, Communications Director, IndieBio / SOSV
- Benjamin Joffe, Partner, SOSV
COVID-19 PORTFOLIO
- Fifty Years: www.fifty.vc/covid
- SOSV: www.sosv.com/covid-startups/
- Khosla Ventures: www.khoslaventures.com/khosla-ventures-entrepreneurs-are-responding-with-amazing-diversity-to-covid-19-solutions-for-societys-needs
Sanofi is a global healthcare leader focused on patients' needs, with over 110,000 employees worldwide. Through mergers and acquisitions from 1973 to 2011, Sanofi has become a diversified healthcare company with businesses in pharmaceuticals, vaccines, consumer healthcare, and animal health. The company's strategy focuses on increasing innovation through R&D, seizing external growth opportunities, and adapting to future challenges through businesses in emerging markets, vaccines, consumer healthcare, diabetes, and animal health. Sanofi is committed to corporate social responsibility through ensuring access to healthcare in developing countries.
Brochure (1) 10th Annual World Stem Cells & Regenerative Medicine Congress Ma...John Redaelli
The Stem Cells 2015 conference will take place from 20-22 May in London, featuring keynote speakers from industry leaders, biotech roundtables, and panels from stem cell foundations. Over 500 meetings are expected among 50+ exhibitors and 60+ speakers discussing commercializing cell therapies and gaining market access. Topics will include innovations in regenerative medicine, manufacturing, and new clinical applications for conditions like diabetes and stroke.
This document provides an overview of a panel discussion on innovative financing trends for European biotechs. The panel will discuss whether EU investors will increase their appetite for risk capital, alternative fundraising options for European companies to achieve more reasonable valuations, and if European companies should seek investment from US markets instead. While European biotech research is strong, US capital markets continue to offer European companies higher valuations, larger investments, and more liquidity compared to domestic exchanges. The panel aims to explore solutions to these regional challenges facing European drug innovators.
Digital Healthcare Partners is a digital health accelerator in Korea that discovers, cultivates, invests in, and connects digital health startups. It provides mentoring, business development support, clinical validation, and investment to early-stage startups. Recent deals include a seed investment in 3billion, a company developing genetic diagnosis services for rare diseases using genome analysis. Global trends in digital health funding in Q1 2017 included large deals in areas like population health, EHR, and e-commerce. The largest deal was Grail's $900M series B for its liquid biopsy cancer diagnostic technology.
This document summarizes the BioVision 2013 conference held in Lyon, France. It discusses several topics related to biomedical research and innovation. Key points include the importance of supporting young researchers, the potential of gene research this century, positive indicators for the healthcare sector in France, and over 200 million euros currently spent on translational research. The conference featured discussions on synergizing research efforts, supporting startups, new medical treatments, and catalyzing innovation through cross-disciplinary approaches. Speakers represented industry, government, and academia and addressed issues like climate change, regulating drug development and access, and enabling new biomanufacturing technologies.
This document summarizes antibiotic resistance data from various studies in Nepal. It finds relatively high rates of resistance in common bacterial pathogens like Streptococcus pneumoniae, Klebsiella pneumoniae, Salmonella spp., Shigella spp., and E. coli. Resistance is increasing over time to first-line drugs like cotrimoxazole and fluoroquinolones. Healthcare-associated infections also show high resistance. Surveillance is limited but suggests resistance is a serious problem. Improving stewardship and establishing ongoing monitoring are recommended to address the growing threat of antibiotic resistance in Nepal.
- Childhood lead poisoning is one of the most common and preventable environmental diseases, with no safe level of exposure.
- Lead has no essential function in the human body and can cause cognitive and behavioral impairments even at low levels.
- Major sources of children's lead exposure include lead added to petrol, lead-based paint in older homes, and lead from industrial activities. Preventing exposure is the best approach.
- Childhood lead poisoning is one of the most common and preventable environmental diseases, with no safe level of exposure.
- Lead has no essential function in the human body and can cause cognitive and behavioral impairments even at low levels.
- Major sources of children's lead exposure include lead added to petrol, lead-based paint in old homes, and lead from industrial activities. Preventing exposure is the best approach.
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Mercurius is named after the roman god mercurius, the god of trade and science. The planet mercurius is named after the same god. Mercurius is sometimes called hydrargyrum, means ‘watery silver’. Its shine and colour are very similar to silver, but mercury is a fluid at room temperatures. The name quick silver is a translation of hydrargyrum, where the word quick describes its tendency to scatter away in all directions.
The droplets have a tendency to conglomerate to one big mass, but on being shaken they fall apart into countless little droplets again. It is used to ignite explosives, like mercury fulminate, the explosive character is one of its general themes.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
5. H ealth-related life sciences : an important sector in the Dutch economy Drugs Diagnostics Devices Companies Revenues FTE Other Total Source: EIM study for EZ [2006] , Voorstel LSG [2006] Preliminary data Biotech Outlook 2011 430 390 75 935 40 12.0 bn 2.7 bn 0.6 bn 15.7 bn 0.4 bn 37,000 12,000 54,600 3,400 ± 150 companies highly innovative Update 2010: >200 companies highly innovative 3% of GDP 2,200
6. The Dutch life sciences and health innovation cluster builds upon a strong knowledge base Excellent biobanks and ‘real life’ data infrastructure 120 mile radius Global players & very high concentration of SMEs Excellent universities
7. 5 of the top 10 European biotech deals are with Dutch companies, with a total value exceeding USD 2 billion
9. Life Sciences & Health Innovation Program Improving the investment and innovation climate in the Dutch life sciences and health sector Hier komt een screenshot van de homepage 7 dec 5000+ unique visitors/month Database for subsidies and funding Benchmark study on clinical trial performance to map the competitive position of the Netherlands BIO - E UROPE S PRING MARCH 14-16, 2011, MILAN, ITALY Thomson Pharma Bio International Convention, Chicago, 2010
EIM Report: Het cluster drugs bestaat uit bedrijven waarvoor geneesmiddelen en vaccins de belangrijkste afzetmarkten vormen. Ongeveer 44% van alle bedrijven (circa 430) maakt hier deel van uit. Zij tekenen voor een gezamenlijke om-zet van € 12 miljard en herbergen circa 37.000 werknemers, waarvan er 6.300 werkzaam zijn op R&D-gebied. In dit cluster zitten vanzelfsprekend ook veel farmaceutische bedrijven Het cluster diagnostics bevat bedrijven waarvoor diagnostische stoffen, bio-informatica, imaging en andere diagnostische apparatuur de belangrijkste deelmarkten zijn. Ongeveer 40% van de bedrijven (circa 390) maakt hier deel van uit. Zij zijn goed voor een totale omzet van € 2,7 miljard en voor een totale werkgelegenheid van ruim 12.000, waaronder bijna 2.000 R&D-werknemers. Het cluster biomedical engineerig & devices herbergt bedrijven waarvoor cel-enigineering, biomaterialen en kunstorganen belangrijke afzetmarkten vormen. Ongeveer 75 bedrijven maken hier deel van uit (7,6% van het to-taal); het cluster is goed voor een omzet van € 560 miljoen. In dit cluster zijn 3.400 personen, waarvan de helft op R&D-gebied. Cluster divers omvat bedrijven die binnen de Life Sciences & Gezondheid sector werkzaam zijn en waarvoor overige medische instrumenten de be-langrijkste afzetmarkt vormen. Ruim 40 bedrijven maken hier deel van uit. Omzet: € 400 miljoen. Dit cluster herbergt 2.200 werkzame personen waar-van ongeveer 10% wordt ingezet op R&D-gebied. drijven, waaronder enkele grote.
That was the past…Today the life sciences sector is not just blooming in Amsterdam, but in the whole of the Netherlands. In 2009 the Netherlands features a highly innovative, world leading, concentrated and growing cluster of life sciences companies academia , covering a wide variety of clinical areas. A recent OECD study showed that the focal areas in the West and South of the Netherlands are among the leading clusters in the world for generation biotech patents
Our approach is paying off In 2008 a strong growth in attracted venture capital against all odds In the top 10 European biotech-Pharma partnerships, 5 involve Dutch SME’s An example: Prosensa and its partnership with GSK - Development and commercialization of RNA based therapeutics for Duchenne Muscular Dystrophy (DMD) - Deal value of upfront and milestone payments USD 655 million